ALMS
Alumis Inc.$5.07-0.53 (-9.46%)Prev Close$5.60·MCap$828.4M·P/E—·Vol1.47M·Yield—
▲
Buys (12M)
12
$50.51M
▼
Sells (12M)
14
$1.57M
◆
Net Activity
Net Buyer
$48.94M
●
Active Insiders
11
last 12 mo
Over the past 12 months, insider activity at Alumis Inc. (ALMS) has been dominated by buying, with 12 insider purchases totaling $50.51M and 14 insider sales totaling $1.57M. The most recent insider transaction was by Goldstein David M (officer: Chief Scientific Officer), who sold $4.1K worth of shares on Nov 4, 2026. Alumis Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $828.4M.
ALMS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Goldstein David M | officer: Chief Scientific Officer | Sell | 629 | $6.52 | $4.1K | 30,341 |
| Nov 4, 2026 | Schroer John R. | officer: Chief Financial Officer | Sell | 794 | $6.52 | $5.2K | 23,924 |
| Nov 4, 2026 | Pangali Sanam | officer: Chief Legal Officer | Sell | 332 | $6.52 | $2.2K | 9,415 |
| Nov 4, 2026 | Drappa Jorn | officer: Chief Medical Officer | Sell | 593 | $6.52 | $3.9K | 56,299 |
| Nov 4, 2026 | Hardiman Roy C. | officer: Chief Business & Strategy Ofcr | Sell | 652 | $6.52 | $4.3K | 207,094 |
| Nov 4, 2026 | Bradley Mark Christopher | officer: Chief Development Officer | Sell | 623 | $6.52 | $4.1K | 47,910 |
| Sep 9, 2026 | AKKARAJU SRINIVAS | director | Sell | 96,131 | $10.55 | $1.01M | 4,663,735 |
| Sep 9, 2026 | AKKARAJU SRINIVAS | director | Buy | 766,651 | $10.78 | $8.27M0.6% OS | 4,937,026 |
| Aug 5, 2026 | Drappa Jorn | officer: Chief Medical Officer | Sell | 2,447 | $26.37 | $64.5K | 56,892 |
| Aug 5, 2026 | Bradley Mark Christopher | officer: Chief Development Officer | Sell | 2,572 | $26.37 | $67.8K | 48,533 |
| Aug 5, 2026 | Goldstein David M | officer: Chief Scientific Officer | Sell | 2,596 | $26.37 | $68.5K | 30,970 |
| Aug 5, 2026 | Pangali Sanam | officer: Chief Legal Officer | Sell | 1,364 | $26.37 | $36.0K | 9,747 |
| Aug 5, 2026 | Schroer John R. | officer: Chief Financial Officer | Sell | 3,282 | $26.37 | $86.5K | 24,718 |
| Aug 5, 2026 | Hardiman Roy C. | officer: Chief Business & Strategy Ofcr | Sell | 2,692 | $26.37 | $71.0K | 207,746 |
| Jul 8, 2026 | Pangali Sanam | officer: Chief Legal Officer | Sell | 5,000 | $28.00 | $140.0K | 11,111-31% |
| Jan 12, 2026 | Foresite Capital Management VI LLC | 10 percent owner | Buy | 411,764 | $17.00 | $7.00M | 5,702,536 |
| Jan 12, 2026 | Foresite Labs, LLC | 10 percent owner | Buy | 411,764 | $17.00 | $7.00M | 5,702,536 |
| Jan 9, 2026 | AKKARAJU SRINIVAS | Director | Buy | 588,235 | $17.00 | $10.00M | 0 |
| Jan 8, 2026 | Tananbaum James B. | Director | Buy | 411,764 | $17.00 | $7.00M | 0 |
| Dec 5, 2025 | AKKARAJU SRINIVAS | Director | Buy | 186,377 | $9.84 | $1.83M | 0 |
| Dec 2, 2025 | AKKARAJU SRINIVAS | Director | Buy | 262,027 | $7.79 | $2.04M | 0 |
| Nov 26, 2025 | AKKARAJU SRINIVAS | Director | Buy | 173,589 | $7.55 | $1.31M | 0 |
| Nov 21, 2025 | Tananbaum James B. | Director | Buy | 72,212 | $7.38 | $532.9K | 0 |
| Nov 20, 2025 | AKKARAJU SRINIVAS | Director | Buy | 125,743 | $7.20 | $905.4K | 0 |
| Nov 17, 2025 | AKKARAJU SRINIVAS | Director | Buy | 241,338 | $6.34 | $1.53M | 0 |
| Nov 17, 2025 | Tananbaum James B. | Director | Buy | 507,874 | $6.09 | $3.09M | 0 |
| Nov 13, 2025 | AKKARAJU SRINIVAS | Director | Buy | 276,179 | $5.25 | $1.45M | 0 |
| May 2, 2025 | AKKARAJU SRINIVAS | Director | Buy | 320,290 | $4.61 | $1.48M | 0 |
| May 2, 2025 | Tananbaum James B. | Director | Buy | 45,000 | $4.50 | $202.3K | 0 |
| Apr 1, 2025 | Babler Martin | President, CEO and Chairman | Buy | 15,650 | $6.44 | $100.7K | 0 |
| Apr 1, 2025 | Colowick Alan | Director | Buy | 18,404 | $7.04 | $129.5K | 0 |
| Jul 1, 2024 | Tananbaum James B. | Director | Buy | 2,500,000 | $16.00 | $40.00M2.0% OS | 0 |
ALMS Insider Buying Activity
The following table shows recent insider purchases of Alumis Inc. (ALMS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | AKKARAJU SRINIVAS | director | Buy | 766,651 | $10.78 | $8.27M0.6% OS | 4,937,026 |
| Jan 12, 2026 | Foresite Capital Management VI LLC | 10 percent owner | Buy | 411,764 | $17.00 | $7.00M | 5,702,536 |
| Jan 12, 2026 | Foresite Labs, LLC | 10 percent owner | Buy | 411,764 | $17.00 | $7.00M | 5,702,536 |
| Jan 9, 2026 | AKKARAJU SRINIVAS | Director | Buy | 588,235 | $17.00 | $10.00M | 0 |
| Jan 8, 2026 | Tananbaum James B. | Director | Buy | 411,764 | $17.00 | $7.00M | 0 |
| Dec 5, 2025 | AKKARAJU SRINIVAS | Director | Buy | 186,377 | $9.84 | $1.83M | 0 |
| Dec 2, 2025 | AKKARAJU SRINIVAS | Director | Buy | 262,027 | $7.79 | $2.04M | 0 |
| Nov 26, 2025 | AKKARAJU SRINIVAS | Director | Buy | 173,589 | $7.55 | $1.31M | 0 |
| Nov 21, 2025 | Tananbaum James B. | Director | Buy | 72,212 | $7.38 | $532.9K | 0 |
| Nov 20, 2025 | AKKARAJU SRINIVAS | Director | Buy | 125,743 | $7.20 | $905.4K | 0 |
| Nov 17, 2025 | AKKARAJU SRINIVAS | Director | Buy | 241,338 | $6.34 | $1.53M | 0 |
| Nov 17, 2025 | Tananbaum James B. | Director | Buy | 507,874 | $6.09 | $3.09M | 0 |
| Nov 13, 2025 | AKKARAJU SRINIVAS | Director | Buy | 276,179 | $5.25 | $1.45M | 0 |
| May 2, 2025 | AKKARAJU SRINIVAS | Director | Buy | 320,290 | $4.61 | $1.48M | 0 |
| May 2, 2025 | Tananbaum James B. | Director | Buy | 45,000 | $4.50 | $202.3K | 0 |
| Apr 1, 2025 | Babler Martin | President, CEO and Chairman | Buy | 15,650 | $6.44 | $100.7K | 0 |
| Apr 1, 2025 | Colowick Alan | Director | Buy | 18,404 | $7.04 | $129.5K | 0 |
| Jul 1, 2024 | Tananbaum James B. | Director | Buy | 2,500,000 | $16.00 | $40.00M2.0% OS | 0 |
ALMS Insider Selling Activity
The following table shows recent insider sales of Alumis Inc. (ALMS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Goldstein David M | officer: Chief Scientific Officer | Sell | 629 | $6.52 | $4.1K | 30,341 |
| Nov 4, 2026 | Schroer John R. | officer: Chief Financial Officer | Sell | 794 | $6.52 | $5.2K | 23,924 |
| Nov 4, 2026 | Pangali Sanam | officer: Chief Legal Officer | Sell | 332 | $6.52 | $2.2K | 9,415 |
| Nov 4, 2026 | Drappa Jorn | officer: Chief Medical Officer | Sell | 593 | $6.52 | $3.9K | 56,299 |
| Nov 4, 2026 | Hardiman Roy C. | officer: Chief Business & Strategy Ofcr | Sell | 652 | $6.52 | $4.3K | 207,094 |
| Nov 4, 2026 | Bradley Mark Christopher | officer: Chief Development Officer | Sell | 623 | $6.52 | $4.1K | 47,910 |
| Sep 9, 2026 | AKKARAJU SRINIVAS | director | Sell | 96,131 | $10.55 | $1.01M | 4,663,735 |
| Aug 5, 2026 | Drappa Jorn | officer: Chief Medical Officer | Sell | 2,447 | $26.37 | $64.5K | 56,892 |
| Aug 5, 2026 | Bradley Mark Christopher | officer: Chief Development Officer | Sell | 2,572 | $26.37 | $67.8K | 48,533 |
| Aug 5, 2026 | Goldstein David M | officer: Chief Scientific Officer | Sell | 2,596 | $26.37 | $68.5K | 30,970 |
| Aug 5, 2026 | Pangali Sanam | officer: Chief Legal Officer | Sell | 1,364 | $26.37 | $36.0K | 9,747 |
| Aug 5, 2026 | Schroer John R. | officer: Chief Financial Officer | Sell | 3,282 | $26.37 | $86.5K | 24,718 |
| Aug 5, 2026 | Hardiman Roy C. | officer: Chief Business & Strategy Ofcr | Sell | 2,692 | $26.37 | $71.0K | 207,746 |
| Jul 8, 2026 | Pangali Sanam | officer: Chief Legal Officer | Sell | 5,000 | $28.00 | $140.0K | 11,111-31% |
ALMS Insiders
Similar Stocks to ALMS
VRTX
Vertex Pharmaceuticals Incorporated
$536.14-0.42%
$138.69B
REGN
Regeneron Pharmaceuticals, Inc.
$948.88-0.62%
$99.23B
MRNA
Moderna, Inc.
$214.97-3.55%
$93.61B
RVMD
Revolution Medicines, Inc.
$166.45-3.42%
$39.08B
INSM
Insmed Incorporated
$122.96+1.38%
$26.58B
UTHR
United Therapeutics Corporation
$585.50-0.96%
$25.18B
INCY
Incyte Corporation
$120.12-0.66%
$24.66B
ALNY
Alnylam Pharmaceuticals, Inc.
$159.51-3.31%
$21.41B